Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficamten. | ...

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. | Vanda Pharmaceuticals’ ...

JSR Life Sciences is parting ways with its CRO business Crown Bioscience, selling the unit to a Chinese clinical lab service ...

Roche has reported another phase 3 win for its oral selective estrogen receptor degrader (SERD). Success at a planned interim ...

The investment bank Jefferies had been running its healthcare conference in London for 14 years as a reasonably intimate ...

Cornerstone Robotics secured about $200 million in its second round of financing this year, which the Hong Kong-based company ...

Medtronic posted a slate of strong quarterly financial results this morning, with its cardiovascular device portfolio pushing ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...

On its face, Biogen’s May 2024 acquisition of Human Immunology Biosciences (HI-Bio) | On its face, there wasn’t much notable ...

Genmab has shed another antibody-drug conjugate from its April 2024 acquisition of ProfoundBio. | Genmab has shed another ...

Through a collaboration with Edwards Lifesciences, Philips is rolling out new artificial intelligence tools designed to ...